Food and Drug Administration vaccine advisers voted unanimously Thursday to support using the same strain composition for primary COVID-19 vaccination and booster doses, a step toward simplifying a U.S. vaccination program that now uses different formulations depending on whether a person is starting a primary series or receiving a booster. The Vaccines and Related Biological Products Advisory Committee voted 21-0 in favor of the harmonization question after reviewing data on current vaccines, bivalent boosters, emerging variants and possible approaches for future updates.

The formal voting question was deliberately narrower than some of the broader changes discussed during the Jan. 26 meeting. Advisers were asked whether the composition of primary-series and booster doses should be harmonized. They were not asked to vote on an annual vaccination schedule, nor did they recommend that every person receive exactly the same number of doses. Those ideas remain under discussion as the FDA considers how to move the program from an emergency-era sequence of product-specific authorizations toward a more predictable system.

A single composition would remove a growing source of complexity

The FDA’s briefing document framed the problem as one of both immunology and implementation. The United States currently uses original, or monovalent, vaccines for primary vaccination while updated bivalent formulations that include components targeting the original virus and Omicron BA.4/BA.5 are used for boosters. That distinction has become increasingly difficult to explain as most of the population has prior vaccination, infection, or both.

FDA staff argued that a common composition could reduce confusion for clinicians and patients, simplify inventory and administration, and make it easier to update vaccines when the virus changes. A separate FDA presentation outlined a possible model in which most people would receive a single dose of an updated vaccine at an interval appropriate to their age and immune status, while some populations — particularly young children, older adults and people with compromised immune systems — could need additional doses.

That framework is not yet policy. Existing Emergency Use Authorizations and vaccine schedules remain in force unless the FDA changes them. The committee’s action is advisory, and the agency is not required to follow its recommendation, although unanimous votes generally carry substantial weight.

Evidence on bivalent boosters shapes the debate

The committee reviewed growing evidence on the safety and effectiveness of the bivalent boosters introduced in the fall. FDA scientists summarized observational data in a presentation comparing original and updated formulations, including protection against symptomatic infection and severe outcomes. The evidence base remains less mature than the randomized trial evidence that supported the first COVID-19 vaccines, in part because variant turnover and high levels of population immunity make traditional efficacy trials more difficult.

Committee members also had to weigh how quickly vaccine composition can be changed against the time required for manufacturing and distribution. The agency’s strain-selection presentation considered a process similar in broad outline to influenza vaccination: experts would review circulating variants and immune data, the FDA would select a composition on a regular timetable, and manufacturers would produce doses in advance of an anticipated seasonal campaign.

COVID-19, however, has not yet settled into the predictable seasonality of influenza. Variants can rise and fall within months, and different lineages can circulate simultaneously. That means any annual process would need enough flexibility to respond when the virus changes more quickly than a manufacturing calendar can accommodate.

One annual dose for most people remains a proposal, not a decision

The FDA has suggested that a simplified program could eventually involve one updated dose for many people each year, with additional doses for populations at higher risk. The proposal received extensive discussion but was not the subject of Thursday’s formal vote. The distinction was emphasized in contemporaneous coverage of the meeting, including a CBS News account that described the committee’s unanimous support for aligning vaccine composition while noting that questions about dosing frequency were left unresolved.

A contemporaneous NPR report likewise stressed that the panel endorsed a simpler product strategy rather than a fully settled annual schedule. For public-health agencies, that distinction matters because recommendations must account for age, prior doses, immune status and the evolving evidence on how long protection against severe disease persists.

The FDA’s published meeting record includes the agenda, background materials and presentations that shaped the discussion. The complete meeting transcript also captures advisers’ concerns about both scientific uncertainty and the practical burden of a schedule that has become difficult for patients and health professionals to follow.

The next decision is how to choose future vaccine strains

With the composition vote complete, the next major policy question is how and when the United States should choose future vaccine strains. FDA officials are considering a spring review that could support a fall vaccination campaign, but the agency must balance the desire for predictability against the possibility that the dominant variant could change after a strain is selected.

The immediate consequence of the Jan. 26 meeting is therefore procedural rather than operational. No existing dose recommendation disappeared Thursday, and no new annual schedule took effect. Instead, the FDA received a clear 21-0 advisory signal that maintaining different antigen compositions for primary and booster vaccination is no longer the preferred long-term structure.

For a vaccination campaign entering its third year, the significance is substantial. The policy challenge is shifting from rapidly deploying first-generation vaccines to maintaining protection in a population with diverse immunity while the virus continues to evolve. A single composition across primary and booster doses could make that system easier to administer, but the harder questions — who needs how many doses, how often, and against which strains — remain to be decided.